| Evox Therapeutics–FTI Consulting: public relations, 202003 service existent by FTI Consulting |
2020-03-26 |
| SutroVax–Abingworth: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Abingworth |
2020-03-26 |
| SutroVax–Medicxi: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Medicxi |
2020-03-26 |
| SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund |
2020-03-26 |
| SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson |
2020-03-26 |
| Takeda–Evox Therapeutics: exosome therapeutics, 202003– collab up to $926m + tiered royalties developm for up to 5 rare disease targets |
2020-03-26 |
| AstraZeneca–Silence Therapeutics: siRNA molecules, 202003– collab r+d strategic alliance $60m upfront + up to $400m for each disease target |
2020-03-25 |
| Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections |
2020-03-25 |
| Silence Therapeutics–AstraZeneca: investment, 202003 equity investment $20m in connection with strategic siRNA alliance |
2020-03-25 |
| Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG |
2020-03-24 |
| Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties |
2020-03-23 |
| DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug r+d |
2020-03-23 |
| Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR |
2020-03-19 |
| BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno |
2020-03-18 |
| OncoOne–SEVERAL: investment, 202003 financing round Series A €13m investors include FFG + AWS + two family offices |
2020-03-18 |
| OncoOne–Trophic Communications: public relations, 202003 service existent by Trophic Communications |
2020-03-18 |
| Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya |
2020-03-17 |
| Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors |
2020-03-17 |
| MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED |
2020-03-17 |
| Pfizer–BioNTech: mRNA-based vaccines, 202003– collab development of COVID-19 vaccine |
2020-03-17 |
| BioNTech–Fosun: investment, 202003 equity investment €44m for 1.58m ordinary shares by Fosun Pharma as part of COVID-19 vaccine collab |
2020-03-16 |
| Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma |
2020-03-16 |
| Tempus Labs–Novo Group: investment, 202003 financing round Series G totalling $100m incl investor Novo Holdings |
2020-03-13 |
| Tempus Labs–SEVERAL: investment, 202003 financing round Series G $100m incl Baillie Gifford + Franklin Templeton + NEA + Novo Holdings + T Rowe Price |
2020-03-13 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| Calixar–SEVERAL: investment, 202003 second financing round €2.5m |
2020-03-09 |
| iAtros–Bavaria (govt): investment, 202003 seed financing round totalling €2m incl investor Bayern Kapital |
2020-03-09 |
| iAtros–High-Tech Gründerfonds: investment, 202003 seed financing round totalling €2m incl investor HTGF |
2020-03-09 |
| iAtros–OTHER: investment, 202003 seed financing round totalling €2m incl several business angels |
2020-03-09 |
| iAtros–SEVERAL: investment, 202003 seed financing round €2m from HTGF + Bayern Kapital + several business angels |
2020-03-09 |
| Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall |
2020-03-09 |
| Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR |
2020-03-06 |
| Autolus–MolMed: viral vectors, 202003– collab multi-year developm + supply of viral vectors by MolMed for T cell cancer therapies |
2020-03-05 |
| Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences |
2020-03-05 |
| Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m |
2020-03-05 |
| AstraZeneca–Voluntis: digital therapeutics, 202003 collab existent |
2020-03-04 |
| BMS–Voluntis: digital therapeutics, 202003–collab developm of digital therapeutics using Theraxium Oncology platform |
2020-03-03 |
| Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher |
2020-03-03 |
| Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED |
2020-03-03 |
| Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition |
2020-03-03 |
| Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen |
2020-03-03 |
| Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology |
2020-03-02 |
| Evonetix–SEVERAL: investment, 202003 financing round Series B $30m (£23m) led by new investor Foresite Capital |
2020-03-02 |
| Immunocore–General Atlantic: investment, 202003 financing round Series B totalling $130m incl new + lead investor General Atlantic |
2020-03-02 |
| Immunocore–SEVERAL: investment, 202003 financing round Series B $130m led by new investor General Atlantic |
2020-03-02 |
| Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System |
2020-03-02 |
| Boehringer–Trutino Biosciences: cancer immunotherapy, 202002– collab research + ww excl license to develop up to 3 candidates using ODC technology |
2020-02-27 |
| Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US |
2020-02-26 |
| FinnGen–AbbVie: genomics, 202002 collab existent AbbVie is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–AstraZeneca: genomics, 202002 collab existent AstraZeneca is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Biogen: genomics, 202002 collab existent Biogen is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–BMS: genomics, 202002 collab existent BMS is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–JnJ: genomics, 202002– collab Janssen new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Maze Therapeutics: genomics, 202002– collab Maze new industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen |
2020-02-25 |
| ImmunOs Therapeutics–Minapharm: biopharma production, 202002– supply €na support developm using DirectedLuck + large-scale production by ProBioGen |
2020-02-25 |
| Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech |
2020-02-25 |
| Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund |
2020-02-25 |
| Scipio Bioscience–Financière Arbevel: investment, 202002 financing round Series A totalling €6m incl new + co-investor Financière Arbevel |
2020-02-25 |
| Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF |
2020-02-25 |
| Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures |
2020-02-25 |
| Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures |
2020-02-25 |
| Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere |
2020-02-25 |
| Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m |
2020-02-21 |
| GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties |
2020-02-20 |
| BIA Separations–Univ Zagreb: purification technology, 202002– commercial license + collab developm of virus + viral vector immunoaffinity purification |
2020-02-19 |
| Servier–Cellectis: T-cell immunotherapy, 202002– collab amendment + expansion ww excl license to develop + commercialise UCARTs tageting CD19 |
2020-02-18 |
| OMass–SEVERAL: investment, 202002 financing round Series A extension £27.5m bringing total Series A to £41.5m |
2020-02-17 |
| Pheno Therapeutics–SEVERAL: investment, 202002– financing round Series A £5m milestone-based over 3 years from Advent Life Sciences + SIB + LifeArc |
2020-02-17 |
| Pencil Biosciences–o2h: investment, 202002 investment by o2h Ventures Therapeutics and AI Fund |
2020-02-15 |
| Pencil Biosciences–United Kingdom (govt): grant, <202002 received Innovate UK grants |
2020-02-15 |
| OncoDNA–Belgium (govt): investment, 202002 financing round Series B totalling €19m incl significant support from co-investor SFPI-FPIM |
2020-02-14 |
| OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest |
2020-02-14 |
| OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III |
2020-02-14 |
| OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB |
2020-02-14 |
| Domainex–Sciad Communications: public relations, 202002 service existent by Sciad |
2020-02-13 |
| NanoPin Technologies–Thermo Fisher: mass spectrometry, 202002– collab developm LC-MS-based workflows for blood-based infectious disease diagnostics |
2020-02-13 |
| Apexbio/Cycloud–Stilla Technologies: digital PCR technology, 202002 distribution existent in China by Apexbio/Cycloud |
2020-02-11 |
| Stilla Technologies–BNP Paribas: investment, 202002 financing round Series B totalling €20m incl existing investor BNP Paribas Développement |
2020-02-11 |
| Stilla Technologies–Eurazeo: investment, 202002 financing round Series B totalling €20m incl existing investor Idinvest Partners |
2020-02-11 |
| Stilla Technologies–Illumina: investment, 202002 financing round Series B totalling €20m incl existing investor Illumina Ventures |
2020-02-11 |
| Stilla Technologies–Kurma: investment, 202002 financing round Series B totalling €20m incl existing investor Kurma Partners |
2020-02-11 |
| Stilla Technologies–LBO France: investment, 202002 financing round Series B totalling €20m incl existing investor LBO France |
2020-02-11 |
| Stilla Technologies–Paris Saclay Seeds: investment, 202002 financing round Series B totalling €20m incl existing investor Paris Saclay Seed Funds |
2020-02-11 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
